Table 1.

Demographic and clinical characteristics of 5,336 men, with existing T2DM, diagnosed with clinically localized prostate cancer from 1995 to 2008

Characteristic	Non-user (n = 3,651)		ADT user (n = 1,685)		p
	No. of patients	%	No. of patients	%
Age at diagnosis in years
Mean (SD)	65 (7)		68 (7)
Race/ethnicity
Non-Hispanic White	1,803	49	879	52
Hispanic	648	18	258	15
Non-Hispanic black	822	23	356	21
All others or unknown	378	10	192	12	0.05
Year of diagnosis
1995–2000	628	17	449	27
2001–2005	1,508	41	739	43
2006–2011	1,515	42	497	29	< 0.001
AUA risk groupa
Low	1,134	31	261	15
Intermediate	1,240	34	657	39
High	1,277	35	767	46	< 0.001
Primary treatment
Radical prostatectomy	1,662	46	366	22
Radiation therapy	1,989	54	1,319	78	< 0.001
Comorbidity count (Elixhauser index, 2 years before diagnosis date)
1	3,155	87	1,412	84
2	328	9	178	11
≥ 3	13	0	7	0
Unknown/missing	155	4	88	5	0.138
Ever use of antidiabetic drugs
Never	884	24	310	18
Ever	2,767	76	1,375	82	< 0.001
Antidiabetic drug type
None	884	24	310	18
Oral only	2,149	59	928	55
Insulin	618	17	447	27	< 0.001
ADT type
Adjuvant ADT only			1,100	65
Salvage ADT only			388	23
Adjuvant & salvage ADT			197	12

^a‡Risk group is defined as low (pre-treatment PSA level 10 ng/mL, Gleason score 6, and a clinical tumor stage of T2a), intermediate (10 ng/mL PSA 20 ng/mL, Gleason score of 7, or T2b), or high (PSA 20 ng/mL, Gleason score 8–10, or T2c–T3a)